Exosomal microRNA‑210 is a potentially non‑invasive biomarker for the diagnosis and prognosis of glioma

Lan,Fengming; Yue,Xiao; Xia,Tingyi

doi:10.3892/ol.2020.11249

Exosomal microRNA‑210 is a potentially non‑invasive biomarker for the diagnosis and prognosis of glioma

Authors:
- Fengming Lan
- Xiao Yue
- Tingyi Xia
View Affiliations

Affiliations: Department of Radiotherapy, Chinese PLA General Hospital, Medical School of Chinese PLA, Beijing 100853, P.R. China, Department of Neurosurgery, The Affiliated Hospital of Xiangnan University, Chenzhou, Hunan 423000, P.R. China
Published online on: January 7, 2020 https://doi.org/10.3892/ol.2020.11249
Pages: 1967-1974

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNAs (miRs) transferred by exosomes can function as non‑invasive potential biomarkers for the diagnosis and prognosis in various types of cancer. The present study examined the diagnostic and prognostic value of serum exosomal‑(exo‑)miR‑210 levels in association with hypoxic conditions in patients with glioma. Serum levels of exo‑miR‑210 were determined by quantitative PCR in samples obtained from patients with glioma. Patients were divided into low‑and high‑expression exo‑miR‑210 groups according to the median expression value. Statistical analyses were conducted to examine the potential value of exo‑miR‑210 in predicting the diagnosis and prognosis of patients with glioma. A significant increase in serum exo‑miR‑210 levels was observed in patients with glioma compared with healthy controls. Additionally, the expression levels of exo‑miR‑210 were increased with ascending pathological grades. Furthermore, expression levels of miR‑210 in serum exosomes from patients with glioblastoma were markedly decreased following surgery and upregulated once more at the recurrences of primary tumors, indicating that exo‑miR‑210 could reflect alterations in malignant glioma loads. In addition, Kaplan‑Meier analysis was performed to analyze overall survival (OS) time. Patients with malignant glioma with high exo‑miR‑210 expression exhibited a poorer OS compared with patients with low expression. Importantly, univariate and multivariate Cox regression analysis revealed that the expression levels of exo‑miR‑210 in glioma serum samples were independently associated with OS. Finally, increased serum exo‑miR‑210 expression was positively associated with high levels of hypoxia‑inducible factor 1a and reflected hypoxia in patients with glioma. In conclusion, serum levels of exo‑miR‑210 may serve as a diagnostic, prognostic and hypoxic biomarker to reflect glioma status and hypoxic signatures.

View Figures

View References

1	Savage N: Searching for the roots of brain cancer. Nature. 561:S50–S51. 2018. View Article : Google Scholar : PubMed/NCBI
2	Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P and Ellison DW: The 2016 world health organization classification of tumors of the central nervous system: A summary. Acta Neuropathol. 131:803–820. 2016. View Article : Google Scholar : PubMed/NCBI
3	Ahmed SU, Carruthers R, Gilmour L, Yildirim S, Watts C and Chalmers AJ: Selective inhibition of parallel DNA damage response pathways optimizes radiosensitization of glioblastoma stem-like cells. Cancer Res. 75:4416–4428. 2015. View Article : Google Scholar : PubMed/NCBI
4	Colwell N, Larion M, Giles AJ, Seldomridge AN, Sizdahkhani S, Gilbert MR and Park DM: Hypoxia in the glioblastoma microenvironment: Shaping the phenotype of cancer stem-like cells. Neuro Oncol. 19:887–896. 2017. View Article : Google Scholar : PubMed/NCBI
5	Majmundar AJ, Wong WJ and Simon MC: Hypoxia-inducible factors and the response to hypoxic stress. Mol Cell. 40:294–309. 2010. View Article : Google Scholar : PubMed/NCBI
6	Wu D, Potluri N, Lu J, Kim Y and Rastinejad F: Structural integration in hypoxia-inducible factors. Nature. 524:303–308. 2015. View Article : Google Scholar : PubMed/NCBI
7	Semenza GL: Hypoxia-inducible factors: Mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci. 33:207–214. 2012. View Article : Google Scholar : PubMed/NCBI
8	Sadri N and Zhang PJ: Hypoxia-inducible factors: Mediators of cancer progression; Prognostic and therapeutic targets in soft tissue sarcomas. Cancers (Basel). 5:320–333. 2013. View Article : Google Scholar : PubMed/NCBI
9	Lan F, Qing Q, Pan Q, Hu M, Yu H and Yue X: Serum exosomal miR-301a as a potential diagnostic and prognostic biomarker for human glioma. Cell Oncol (Dordr). 41:25–33. 2018. View Article : Google Scholar : PubMed/NCBI
10	Yue X, Cao D, Lan F, Pan Q, Xia T and Yu H: MiR-301a is activated by the Wnt/β-catenin pathway and promotes glioma cell invasion by suppressing SEPT7. Neuro Oncol. 18:1288–1296. 2016. View Article : Google Scholar : PubMed/NCBI
11	Lan F, Yu H, Hu M, Xia T and Yue X: miR-144-3p exerts anti-tumor effects in glioblastoma by targeting c-Met. J Neurochem. 135:274–286. 2015. View Article : Google Scholar : PubMed/NCBI
12	Xu K, Zhan Y, Yuan Z, Qiu Y, Wang H, Fan G, Wang J, Li W, Cao Y, Shen X, et al: Hypoxia induces drug resistance in colorectal cancer through the HIF-1α/miR-338-5p/IL-6 feedback loop. Mol Ther. 2019.(Epub ahead of print). View Article : Google Scholar
13	Zhou Y, Xu Q, Shang J, Lu L and Chen G: Crocin inhibits the migration, invasion, and epithelial-mesenchymal transition of gastric cancer cells via miR-320/KLF5/HIF-1α signaling. J Cell Physiol. 234:17876–17885. 2019. View Article : Google Scholar : PubMed/NCBI
14	Zhao Q, Li Y, Tan BB, Fan LQ, Yang PG and Tian Y: HIF-1α induces multidrug resistance in gastric cancer cells by inducing MiR-27a. PLoS One. 10:e01327462015. View Article : Google Scholar : PubMed/NCBI
15	Ke HL, Li WM, Lin HH, Hsu WC, Hsu YL, Chang LL, Huang CN, Li CC, Chang HP, Yeh HC, et al: Hypoxia-regulated MicroRNA-210 overexpression is associated with tumor development and progression in upper tract urothelial carcinoma. Int J Med Sci. 14:578–584. 2017. View Article : Google Scholar : PubMed/NCBI
16	He C, Wang L, Zhang J and Xu H: Hypoxia-inducible microRNA-224 promotes the cell growth, migration and invasion by directly targeting RASSF8 in gastric cancer. Mol Cancer. 16:352017. View Article : Google Scholar : PubMed/NCBI
17	Ge X, Liu X, Lin F, Li P, Liu K, Geng R, Dai C, Lin Y, Tang W, Wu Z, et al: MicroRNA-421 regulated by HIF-1α promotes metastasis, inhibits apoptosis, and induces cisplatin resistance by targeting E-cadherin and caspase-3 in gastric cancer. Oncotarget. 7:24466–24482. 2016. View Article : Google Scholar : PubMed/NCBI
18	Benej M, Pastorekova S and Pastorek J: Carbonic anhydrase IX: Regulation and role in cancer. Subcell Biochem. 75:199–219. 2014. View Article : Google Scholar : PubMed/NCBI
19	Ziffels B, Stringhini M, Probst P, Fugmann T, Sturm T and Neri D: Antibody-based delivery of cytokine payloads to carbonic anhydrase IX leads to cancer cures in immunocompetent tumor-bearing mice. Mol Cancer Ther. 18:1544–1554. 2019. View Article : Google Scholar : PubMed/NCBI
20	Meng W, Hao Y, He C, Li L and Zhu G: Exosome-orchestrated hypoxic tumor microenvironment. Mol Cancer. 18:572019. View Article : Google Scholar : PubMed/NCBI
21	Hoshino A, Costa-Silva B, Shen TL, Rodrigues G, Hashimoto A, Tesic Mark M, Molina H, Kohsaka S, Di Giannatale A, Ceder S, et al: Tumour exosome integrins determine organotropic metastasis. Nature. 527:329–335. 2015. View Article : Google Scholar : PubMed/NCBI
22	Nouraee N, Khazaei S, Vasei M, Razavipour SF, Sadeghizadeh M and Mowla SJ: MicroRNAs contribution in tumor microenvironment of esophageal cancer. Cancer Biomarkers. 16:367–376. 2016. View Article : Google Scholar : PubMed/NCBI
23	Xiao GY, Cheng CC, Chiang YS, Cheng WT, Liu IH and Wu SC: Exosomal miR-10a derived from amniotic fluid stem cells preserves ovarian follicles after chemotherapy. Sci Rep. 6:231202016. View Article : Google Scholar : PubMed/NCBI
24	Khalid MA, Achakzai IK, Ahmed Khan S, Majid Z, Hanif FM, Iqbal J, Laeeq SM and Luck NH: The use of karnofsky performance status (KPS) as a predictor of 3 month post discharge mortality in cirrhotic patients. Gastroenterol Hepatol Bed Bench. 11:301–305. 2018.PubMed/NCBI
25	Yue X, Lan F, Hu M, Pan Q, Wang Q and Wang J: Downregulation of serum microRNA-205 as a potential diagnostic and prognostic biomarker for human glioma. J Neurosurg. 124:122–128. 2016. View Article : Google Scholar : PubMed/NCBI
26	Eustace A, Irlam JJ, Taylor J, Denley H, Agrawal S, Choudhury A, Ryder D, Ord JJ, Harris AL, Rojas AM, et al: Necrosis predicts benefit from hypoxia-modifying therapy in patients with high risk bladder cancer enrolled in a phase III randomised trial. Radiother Oncol. 108:40–47. 2013. View Article : Google Scholar : PubMed/NCBI
27	Lai NS, Wu DG, Fang XG, Lin YC, Chen SS, Li ZB and Xu SS: Serum microRNA-210 as a potential noninvasive biomarker for the diagnosis and prognosis of glioma. Br J Cancer. 112:1241–1246. 2015. View Article : Google Scholar : PubMed/NCBI
28	Dang K and Myers KA: The role of hypoxia-induced miR-210 in cancer progression. Int J Mol Sci. 16:6353–6372. 2015. View Article : Google Scholar : PubMed/NCBI
29	Yang W, Ma J, Zhou W, Zhou X, Cao B, Fan D and Hong L: Biological implications and clinical value of mir-210 in gastrointestinal cancer. Expert Rev Gastroenterol Hepatol. 11:539–548. 2017. View Article : Google Scholar : PubMed/NCBI
30	Camps C, Saini HK, Mole DR, Choudhry H, Reczko M, Guerra-Assunção JA, Tian YM, Buffa FM, Harris AL, Hatzigeorgiou AG, et al: Integrated analysis of microRNA and mRNA expression and association with HIF binding reveals the complexity of microRNA expression regulation under hypoxia. Mol Cancer. 13:282014. View Article : Google Scholar : PubMed/NCBI
31	Agrawal R, Pandey P, Jha P, Dwivedi V, Sarkar C and Kulshreshtha R: Hypoxic signature of microRNAs in glioblastoma: Insights from small RNA deep sequencing. BMC Genomics. 15:6862014. View Article : Google Scholar : PubMed/NCBI
32	Irlam-Jones JJ, Eustace A, Denley H, Choudhury A, Harris AL, Hoskin PJ and West CM: Expression of miR-210 in relation to other measures of hypoxia and prediction of benefit from hypoxia modification in patients with bladder cancer. Br J Cancer. 115:571–578. 2016. View Article : Google Scholar : PubMed/NCBI
33	Li D, Liu J, Guo B, Liang C, Dang L, Lu C, He X, Cheung HY, Xu L, Lu C, et al: Osteoclast-derived exosomal miR-214-3p inhibits osteoblastic bone formation. Nat Commun. 7:108722016. View Article : Google Scholar : PubMed/NCBI
34	Munagala R, Aqil F and Gupta RC: Exosomal miRNAs as biomarkers of recurrent lung cancer. Tumour Biol. 37:10703–10714. 2016. View Article : Google Scholar : PubMed/NCBI
35	Zhou W, Fong MY, Min Y, Somlo G, Liu L, Palomares MR, Yu Y, Chow A, O'Connor ST, Chin AR, et al: Cancer-secreted miR-105 destroys vascular endothelial barriers to promote metastasis. Cancer Cell. 25:501–515. 2014. View Article : Google Scholar : PubMed/NCBI
36	Tanaka Y, Kamohara H, Kinoshita K, Kurashige J, Ishimoto T, Iwatsuki M, Watanabe M and Baba H: Clinical impact of serum exosomal microRNA-21 as a clinical biomarker in human esophageal squamous cell carcinoma. Cancer. 119:1159–1167. 2013. View Article : Google Scholar : PubMed/NCBI
37	Matsumura T, Sugimachi K, Iinuma H, Takahashi Y, Kurashige J, Sawada G, Ueda M, Uchi R, Ueo H, Takano Y, et al: Exosomal microRNA in serum is a novel biomarker of recurrence in human colorectal cancer. Br J Cancer. 113:275–281. 2015. View Article : Google Scholar : PubMed/NCBI
38	Shi R, Wang PY, Li XY, Chen JX, Li Y, Zhang XZ, Zhang CG, Jiang T, Li WB, Ding W and Cheng SJ: Exosomal levels of miRNA-21 from cerebrospinal fluids associated with poor prognosis and tumor recurrence of glioma patients. Oncotarget. 6:26971–26981. 2015. View Article : Google Scholar : PubMed/NCBI
39	Huang X, Yuan T, Liang M, Du M, Xia S, Dittmar R, Wang D, See W, Costello BA, Quevedo F, et al: Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer. Eur Urol. 67:33–41. 2015. View Article : Google Scholar : PubMed/NCBI
40	Yoshikawa M, Iinuma H, Umemoto Y, Yanagisawa T, Matsumoto A and Jinno H: Exosome-encapsulated microRNA-223-3p as a minimally invasive biomarker for the early detection of invasive breast cancer. Oncol Lett. 15:9584–9592. 2018.PubMed/NCBI
41	Yang H, Fu H, Wang B, Zhang X, Mao J, Li X, Wang M, Sun Z, Qian H and Xu W: Exosomal miR-423-5p targets SUFU to promote cancer growth and metastasis and serves as a novel marker for gastric cancer. Mol Carcinog. 57:1223–1236. 2018. View Article : Google Scholar : PubMed/NCBI
42	Bavelloni A, Ramazzotti G, Poli A, Piazzi M, Focaccia E, Blalock W and Faenza I: MiRNA-210: A current overview. Anticancer Res. 37:6511–6521. 2017.PubMed/NCBI
43	Ren CX, Leng RX, Fan YG, Pan HF, Wu CH and Ye DQ: MicroRNA-210 and its theranostic potential. Expert Opin Ther Targets. 20:1325–1338. 2016. View Article : Google Scholar : PubMed/NCBI
44	Bonora M, Wieckowsk MR, Chinopoulos C, Kepp O, Kroemer G, Galluzzi L and Pinton P: Molecular mechanisms of cell death: Central implication of ATP synthase in mitochondrial permeability transition. Oncogene. 34:16082015. View Article : Google Scholar : PubMed/NCBI
45	Zhang S, Lai N, Liao K, Sun J and Lin Y: MicroRNA-210 regulates cell proliferation and apoptosis by targeting regulator of differentiation 1 in glioblastoma cells. Folia Neuropathol. 53:236–244. 2015. View Article : Google Scholar : PubMed/NCBI
46	Kulshreshtha R, Ferracin M, Wojcik SE, Garzon R, Alder H, Agosto-Perez FJ, Davuluri R, Liu CG, Croce CM, Negrini M, et al: A microRNA signature of hypoxia. Mol Cell Biol. 27:1859–1867. 2007. View Article : Google Scholar : PubMed/NCBI
47	Ying Q, Liang L, Guo W, Zha R, Tian Q, Huang S, Yao J, Ding J, Bao M, Ge C, et al: Hypoxia-inducible microRNA-210 augments the metastatic potential of tumor cells by targeting vacuole membrane protein 1 in hepatocellular carcinoma. Hepatology. 54:2064–2075. 2011. View Article : Google Scholar : PubMed/NCBI
48	Cheng HH, Mitchell PS, Kroh EM, Dowell AE, Chéry L, Siddiqui J, Nelson PS, Vessella RL, Knudsen BS, Chinnaiyan AM, et al: Circulating microRNA profiling identifies a subset of metastatic prostate cancer patients with evidence of cancer-associated hypoxia. PLoS One. 8:e692392013. View Article : Google Scholar : PubMed/NCBI
49	Martin RC, Gerstenecker A, Nabors LB, Marson DC and Triebel KL: Impairment of medical decisional capacity in relation to karnofsky performance status in adults with malignant brain tumor. Neurooncol Pract. 2:13–19. 2015.PubMed/NCBI